Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 55 of 179 for:    DCLRE1C

The Safety and Efficacy of OPC-64005 in the Treatment of Adult Attention-deficit/Hyperactivity Disorder

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03324581
Recruitment Status : Completed
First Posted : October 27, 2017
Last Update Posted : January 3, 2019
Sponsor:
Information provided by (Responsible Party):
Otsuka Pharmaceutical Development & Commercialization, Inc.

Brief Summary:
A trial to assess the safety and efficacy of OPC-64005 in the treatment of Adult Attention-deficit/Hyperactivity Disorder

Condition or disease Intervention/treatment Phase
Adult Attention Deficit Hyperactivity Disorder Drug: OPC-64005 Drug: Atomoxetine Drug: Placebo Phase 2

Detailed Description:
A multicenter, randomized, double-blind, active- and placebo-controlled, parallel-design trial.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 239 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 2, Multicenter, Randomized, Double-blind, Active- and Placebo-controlled Trial of the Safety and Efficacy of OPC-64005 in the Treatment of Adult Attention-deficit/Hyperactivity Disorder
Actual Study Start Date : November 28, 2017
Actual Primary Completion Date : October 31, 2018
Actual Study Completion Date : October 31, 2018


Arm Intervention/treatment
Experimental: OPC-64005
20 mg tablet dose, titrated up to a max of 30 mg, daily, oral
Drug: OPC-64005
Tablet

Active Comparator: Atomoxetine
40 mg capsule titrated up to 80 mg, daily, oral
Drug: Atomoxetine
Capsule

Placebo Comparator: Placebo
tablet/capsule, daily, oral
Drug: Placebo
Tablet/Capsule




Primary Outcome Measures :
  1. Conners' Adult ADHD Rating Scales-Observer: Screening Version (CAARS-O:SV) [Efficacy] [ Time Frame: Up to 56 days or early termination ]
    18-item ADHD symptom score will be assessed to compare experimental group to active comparator; Total Score: Min score: 0, Max score: 54. Individual item scores: Min score: 0, max score: 3. Best outcome - Score = 0, Worse outcome - Score = 3. Total score is sum of individual scores.


Other Outcome Measures:
  1. CAARS-O:SV [ Time Frame: Up to 56 days or early termination ]
    Change in score will be assessed on experimental versus active comparator & placebo. Total Score: Minimum: 0, Maximum: 54. Individual Score: Minimum: 0, Maximum: 3. Score of 0 is best outcome, score of 3 is worse outcome. Total score is sum of individual scores.

  2. Adult ADHD Investigator Symptom Rating Scale (AISRS) With Adult Prompts [ Time Frame: Up to 56 days or early termination ]
    Change in score will be assessed on experimental versus active comparator & placebo. Total Score: Minimum: 0, maximum: 54. Individual scores: minimum: 0, maximum: 3. Score of 0 is best outcome, score of 3 is worse outcome. Total score is sum of individual scores.

  3. Clinical Global Impression -Severity of Illness Scale (CGI-S) Score [ Time Frame: Up to 56 days or early termination ]
    Change in score will be assessed on experimental versus active comparator & placebo. Minimum Score: 1, Maximum Score: 7. Score of 1 is best outcome, score of 7 is worse outcome.

  4. Clinical Global Impression - Global Improvement Scale (CGI-I) Score [ Time Frame: Up to 56 days or early termination ]
    Change in score will be assessed on experimental versus active comparator & placebo. Minimum Score: 1, Maximum Score: 7. Score of 1 is best outcome, score of 7 is worse outcome.

  5. Conners' Adult ADHD Rating Scales-Self-Report: Screening Version (CAARS-S:SV) [ Time Frame: Up to 56 days or early termination ]
    Change in score will be assessed on experimental versus active comparator & placebo. Total Score: Minimum: 0, Maximum: 54. Individual Score: Minimum: 0, Maximum: 3. Score of 0 is best outcome, score of 3 is worse outcome. Total score is sum of individual scores.

  6. Adult ADHD Quality of Life Scale (AAQoL) [ Time Frame: Up to 56 days or early termination ]
    Change in score will be assessed on experimental versus active comparator & placebo. 6 item scale; Individual Score: Minimum: 1, Maximum: 5 additional option of "not applicable" for 1 sub-question. Outcome measure vary by question, some will be: 1 - best outcome, 5 - worse outcome; others will be 1 - worse outcome, 5 - best outcome.

  7. Drug Effects Questionnaire (DEQ) [ Time Frame: Up to 56 days or early termination ]
    Change in score will be assessed on experimental versus active comparator & placebo to determine potential for abuse liability and dependence. Visual analog scale from 0 to 100. Scale is not quantifiable by "better" or "worse" as it is a subjective question on the subject's feelings about the medication.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria (Screening):

  • Male and female outpatients 18 to 55 years of age, inclusive, at the time of informed consent.
  • Subjects with a primary Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5) diagnosis of ADHD (including predominantly inattentive presentation, hyperactive presentation, and combined presentations) as confirmed by the Adult ADHD Clinical Diagnostic Scale (ACDS) v 1.2.
  • Subjects willing to discontinue all prohibited psychotropic medication starting from the time of signing the informed consent and up to the 30 (+ 2)-day follow-up period.

Exclusion Criteria:

  • Subjects with a history of inadequate response or suboptimal tolerability to atomoxetine.
  • Subjects who report allergies (lifetime treatment history) to stimulant or nonstimulant ADHD medications.
  • Subjects with other DSM-5 disorders including psychosis (current or lifetime), bipolar disorder (current or lifetime), current major depressive disorder, or current panic disorder; or another psychiatric diagnosis that the investigator believes is primary or that will confound efficacy or safety assessments of the trail or interfere with participation in the trial otherwise.
  • Subjects with a clinically significant current DSM-5 diagnosis of borderline, antisocial, paranoid, schizoid, schizotypal, histrionic, narcissistic, avoidant, obsessive compulsive, or dependent personality disorders.
  • Subjects who currently have clinically significant dermatological, neurological, hepatic, renal, metabolic, hematological, immunological, cardiovascular, pulmonary, or gastrointestinal disorders such as any history of myocardial infarction, congestive heart failure, HIV seropositive status/acquired immunodeficiency syndrome, or active or chronic hepatitis B or C.
  • Subjects with a history of obstructive sleep apnea.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03324581


  Show 27 Study Locations
Sponsors and Collaborators
Otsuka Pharmaceutical Development & Commercialization, Inc.

Layout table for additonal information
Responsible Party: Otsuka Pharmaceutical Development & Commercialization, Inc.
ClinicalTrials.gov Identifier: NCT03324581     History of Changes
Other Study ID Numbers: 277-201-00001
First Posted: October 27, 2017    Key Record Dates
Last Update Posted: January 3, 2019
Last Verified: January 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Otsuka Pharmaceutical Development & Commercialization, Inc.:
ADHD
ADD

Additional relevant MeSH terms:
Layout table for MeSH terms
Disease
Attention Deficit Disorder with Hyperactivity
Hyperkinesis
Pathologic Processes
Attention Deficit and Disruptive Behavior Disorders
Neurodevelopmental Disorders
Mental Disorders
Dyskinesias
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Atomoxetine Hydrochloride
Adrenergic Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Adrenergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs